ZD1839 ('Iressa')1,2 as an anticancer agent

Drugs

Volumn 60, Issue SUPPL. 1, 2000, Pages 33-40

  Baselga, J ^a   Averbuch, S D ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL DIVISION; DRUG EFFECT; LUNG TUMOR; MOUSE; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; REVIEW; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; MICE; QUINAZOLINES; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0033763084     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060001-00004     Document Type: Conference Paper

References (27)

1. The ErbB signaling network: Receptor heterodimerization in development and cancer
2. Regulation of signal transduction and signal diversity by receptor oligomerization
3. The role of polypeptide growth factors in human carcinomas; new targets for a novel pharmacological approach
4. Growth factors and cancer
5. EGF receptor
6. The epidermal growth factor receptor and its inhibition in cancer therapy
7. Epidermal growth factor-related peptides and their receptors in human malignancies
8. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
9. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene
10. Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)
11. Tyrosine kinases and their interactions with signalling proteins
12. ZD1839 ('Iressa') a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): Inhibition of c-fos mRNA, an inter-mediate marker of EGFR activation, correlates with tumor growth inhibition
13. 6-amino-4(3-methyl-phenylamino)- quinazoline: An EGF receptor tyrosine kinase inhibitor with activity in a range of human tumour xenografts
14. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, upregulates p27(Kip1) inducing G1 arrest and enhancing the antitumor effect of Interferon α
15. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-CdK2 complex formation: Receptor overexpression does not determine growth dependency
16. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
17. Antitumour activity of ZD1839 ('Iressa') in combination with cisplatin in NIH3T3 cells expressing human epidermal growth factor receptor
18. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (Iressa(TM)), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
19. EGFR tyrosine kinase inhibition decreases epithelial proliferation in DCIS of the breast, whereas c-erbB2 blockade does not
20. Phase I data of ZD1839 - An oral epidermal growth factor receptor tyrosine kinase inhibitor
21. ZD1839 ('Iressa'), an oral EGFR-TKI (epidermal growth factor tyrosine kinase inhibitor): Pharmacokinetics in a Phase I study of patients with advanced cancer
22. NCIC CTG IND.122: A two-part Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839
23. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability
24. A Phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours
25. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a Phase I study
26. Chemotherapy for non-small cell lung cancer: Have we reached a new plateau?
27. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer: A historical perspective and the eastern cooperative oncology group experience